Bristol Myers Squibb will use artificial intelligence to develop clinical trial protocols in partnership with Faro Health, marking the drugmaker’s second AI-focused deal in as many months. The multiyear collaboration is centered on Faro converting narrative protocol components into structured digital assets for downstream AI drafting, validation, and optimization. BMS said the approach reflects an industry shift away from document-based development. Faro’s technology is also reported to help align protocols with industry standards such as the Tufts Center for the Study of Drug Development framework, including simulated scheduling activities and research site assessments. From an operational standpoint, the coverage highlights BMS positioning Faro’s platform as a system of record for structured protocol design across its drug development organization—aiming to improve consistency and accelerate turnaround while retaining human oversight.